Navigation Links
CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients
Date:10/7/2008

ing pathological inflammation, and excess TNF-alpha production has been directly implicated in a wide variety of diseases. UCB is developing CIMZIA in rheumatoid arthritis and other autoimmune disease indications. CIMZIA was approved in April 2008 for reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderate to severe active disease who have had an inadequate response to conventional therapy. CIMZIA is a registered trademark of UCB PHARMA S.A. For full prescribing information, please visit http://www.ucb-group.com.

Tuberculosis (frequently disseminated or extrapulmonary at clinical presentation), invasive fungal infections, and other opportunistic infections, have been observed in patients receiving CIMZIA. Some of these infections have been fatal. Anti-tuberculosis treatment of patients with latent tuberculosis infection reduces the risk of reactivation in patients receiving treatment with TNF blockers such as CIMZIA. However, active tuberculosis has developed in patients receiving CIMZIA whose tuberculin test was negative. Evaluate patients for tuberculosis risk factors and test for latent tuberculosis infection prior to initiating CIMZIA and during therapy. Initiate treatment of latent tuberculosis infection prior to therapy with CIMZIA. Monitor patients receiving CIMZIA for signs and symptoms of active tuberculosis, including patients who tested negative for latent tuberculosis infection. Consider anti-tuberculosis therapy prior to initiation of CIMZIA in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed.

Serious infections, sepsis, and cases of opportunistic infections, including fatalities, have been reported in patients receiving TNF blockers, including CIMZIA. Infections have been reported in patients receiving CIMZIA alone or in conjunction with immunosuppressive age
'/>"/>

SOURCE UCB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
2. Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohns Disease
3. CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohns Patients
4. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
5. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
6. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
7. Raptor Pharmaceuticals Provides Update of Product Programs
8. Monogram Provides Update on Trofile(TM) Co-Receptor Tropism Assay
9. Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial
10. Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
11. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... THE WOODLANDS, Texas , Nov. 26, 2014 ... LXRX ) today announced the completion of previously ... of $280.0 million.  After fees and estimated offering ... million from the transactions.  The transactions consisted of: ... shares of common stock, pursuant to a registration ...
(Date:11/26/2014)... Nov. 26, 2014  Avanir Pharmaceuticals, Inc. (NASDAQ: ... Food and Drug Administration (FDA) has issued a ... (NDA) for AVP-825. AVP-825 is an investigational drug-device ... intranasally utilizing a novel Breath Powered delivery technology. ... and consistent with the preliminary feedback announced on ...
(Date:11/26/2014)... Investor-Edge has initiated coverage on the following equities: VIVUS ... HZNP ), Endocyte Inc. (NASDAQ: ECYT ... Theravance Inc. (NASDAQ: THRX ). Free research on ... . On Tuesday, November 25, 2014, the NASDAQ Composite ... edged 0.02% lower, to finish the day at 17,814.94, and ...
Breaking Medicine Technology:Lexicon Announces Completion Of $280 Million In Financing Transactions 2Lexicon Announces Completion Of $280 Million In Financing Transactions 3Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 2Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 3Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 2Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 5
... Inc. announced an agreement with the United States Department of ... prescription medication for patients with heart failure. ... plea to a single misdemeanor violation of the Food, Drug ... fine. Scios acknowledges that NATRECOR® was misbranded and ...
... Oct. 5, 2011 SV Life Sciences ("SVLS") today announced the ... joins SVLS with more than 26 years of experience in ... excited to welcome Dr. Dreismann to SVLS," said Lutz Giebel, ... and focus on investments in the diagnostics space. We believe ...
Cached Medicine Technology:SV Life Sciences Appoints Veteran Diagnostics Professional Dr. Heiner Dreismann as Venture Partner 2
(Date:11/28/2014)... 2014 UniWigs.com, a leader in the wig industry, ... to the next Monday. This promotion features: , ... items up to 70% off (no coupon code needed), ... Free shipping on orders over $49 , Visit http://www.uniwigs.com ... from Nov. 28th to Dec. 1st and the first 100 shoppers ...
(Date:11/28/2014)... November 28, 2014 An inventor from Flint, ... to day. "I got this idea while lying in a ... bathroom," he said. , The Bed Buddy provides a more ... to the bathroom. It eliminates the need to leave the ... comfort and dignity. Easy to use and producible in design ...
(Date:11/28/2014)... 28, 2014 talklocal ( http://www.talklocal.com ... the right service professionals by phone in about 90 seconds. ... least two tornadoes were reported to have touched down just ... was reported following the tornadoes, Denver residents now know all ... Having TalkLocal is like having local pros in over 50 ...
(Date:11/28/2014)... November 28, 2014 This report ... market along with the definite portrayal of the ... point depiction of various variables driving the development ... difficulties blocking the development of the business. ... , According to the report "Worldwide Dental ...
(Date:11/27/2014)... (PRWEB) November 28, 2014 One ... implant dentistry. The market for implant dentistry comprises ... tools/instruments. The global market for dental care is ... equipments. The dental equipment segment is composed of ... of contents at: http://www.researchmoz.us/global-dental-market-report-2014-edition-report.html , The ...
Breaking Medicine News(10 mins):Health News:Pre-X'mas Crazy Sale Starts from $0 at UniWigs.com 2Health News:TalkLocal Launches In Denver A Week After Multiple Tornadoes Hit Near City 2Health News:Global Dental Market Report 2014 Edition Now Available at MarketReportsOnline.com 2Health News:Global Dental Market Report 2014 Edition Now Available at MarketReportsOnline.com 3Health News:Dental Market Research Report 2014 - Global Industry Size, Share, Trends, Growth, Retail Sales Value and Forecast by Researchmoz.us 2Health News:Dental Market Research Report 2014 - Global Industry Size, Share, Trends, Growth, Retail Sales Value and Forecast by Researchmoz.us 3
... to be more effective than placebos in treating rapid ... study , which included 38 non-schizophrenic, non-bipolar women with ... 51 was conducted by researchers from various universities in ... shift, impulsivity and aggression when given fluvoxamine or a ...
... a national survey of more than 149,000 Americans including 23,000 ... 25% of adults with disabilities, compared to 16 per cent ... defined as having a Body Mass Index greater than 32. ... mobility difficulties and those who had not received exercise counselling ...
... on both mice and humans are showing why some people absorb ... if you eat a fatty meal or snack - a fried ... you absorb is strongly influenced by your genes. Experts know that ... fat diet is bad for you. But little has been discovered ...
... in there study are trying to observe why surgery ... ongoing. It's long been known that some older people develop ... - a condition known as Post Operative Cognitive Dysfunction (POCD).Often ... same' as they were before surgery. It was assumed, at ...
... observed that a drug already being used to treat ... male contraceptive. Researchers hypothesized N-butyldeoxynojirimycin, or NB-DNJ, which has ... work// as a male contraceptive because it affects the ... tested their theory in an animal study involving mice. ...
... the eye has prevented and stopped autoimmune eye disease in ... treatments for other// autoimmune diseases such as multiple sclerosis and ... Institute in Boston found the factor alpha-MSH can be harnessed ... prevent the onset of and stop the progression of uveitis ...
Cached Medicine News:
Hibbs Retractor with sharp teeth. Used for deep soft tissue retraction....
A general purpose instrument for use around the femur and acetabulum....
The Wire Cutters are designed to cut Kirschner wires up to 2.5 mm diameter easily and smoothly. They are particularly useful for external fixation applications. The Wire Cutters shear fixation wires ...
The double action wire cutter has both side and end cutting capabilities....
Medicine Products: